

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



Duality Biotherapeutics, Inc.

映恩生物

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock code: 9606)

ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE RMB SHARE ISSUE

This announcement is made by Duality Biotherapeutics, Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated October 17, 2025, April 13, 2026 and June 10, 2026 and the circular of the Company dated April 14, 2026, in respect of, among others, matters relating to the RMB Share Issue of the Company. Unless otherwise defined in this announcement, terms used herein shall have the same meanings as defined in such announcements and circular.

The Company has submitted the application materials in respect of the RMB Share Issue, including (among others) the Initial Public Offering of RMB ordinary shares (A Shares) and Listing on the Science and Technology Innovation Board Prospectus (Application Proof) (the “**A Share Prospectus**”), to the Shanghai Stock Exchange, and has recently received a letter of acceptance issued by the Shanghai Stock Exchange regarding the Company’s application for the RMB Share Issue. The A Share Prospectus will be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>).

The RMB Share Issue is subject to approval by the necessary Regulatory Approvals and thus may or may not proceed. Shareholders and potential investors of the Company should be aware that there is no assurance that the RMB Share Issue will materialise or as to when it may materialise. Shareholders and potential investors of the Company should exercise caution when dealing in the Shares.

Further announcement(s) will be made by the Company in accordance with the Listing Rules and other applicable laws and regulations of any material updates and progress in connection with the RMB Share Issue as and when appropriate. This announcement is for information purposes only and does not and is not intended to constitute any invitation or offer to acquire, purchase or subscribe for the Share(s).

By order of the Board
Duality Biotherapeutics, Inc.
Dr. ZHU Zhongyuan
*Chairman of the Board, Executive
Director and Chief Executive Officer*

Hong Kong, June 12, 2026

As at the date of this announcement, the Board of the Company comprises (i) Dr. ZHU Zhongyuan, Mr. ZHANG Shaoren and Dr. HUA Haiqing as executive directors; (ii) Mr. CAI Zhiyang and Dr. YU Tao as non-executive directors; and (iii) Mr. XIE Dong, Mr. GAO Fengyong and Ms. CHUAI Shuyin as independent non-executive directors.